Systematic analysis of potential targets for immunotherapy in acute myeloid leukemia.
Christopher S. Hourigan(National Heart Lung and Blood Institute), A. John Barrett(National Institutes of Health), Amir T. Fathi(University of Southern California), B. Douglas Smith(Johns Hopkins University), Sawa Ito(National Institutes of Health), Stephen A. Strickland(Vanderbilt University), Heidi May Sardon(National Heart Lung and Blood Institute), Hossein Sadrzadeh(Boston University), Medha Bhagwat(National Institutes of Health), Meghali Goswami(National Institutes of Health), Judith E. Karp(Emory University), Nawal W. Alkharouf(National Heart Lung and Blood Institute), James W. Fraser(Harvard University), Bipin N. Savani(Vanderbilt University Medical Center), Qin Lu(Soochow University), J. Phillip McCoy(National Heart Lung and Blood Institute), Allan D. Hess(Johns Hopkins University), Ann L. Williams(National Heart Lung and Blood Institute)
Cited by 0
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k